Skip to main content

Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Publication ,  Journal Article
Weller, M; Roth, P; Preusser, M; Wick, W; Reardon, DA; Platten, M; Sampson, JH
Published in: Nat Rev Neurol
June 2017

Astrocytic and oligodendroglial gliomas are intrinsic brain tumours characterized by infiltrative growth and resistance to classic cancer therapies, which renders them inevitably lethal. Glioblastoma, the most common type of glioma, also exhibits neoangiogenesis and profound immunosuppressive properties. Accordingly, strategies to revert glioma-associated immunosuppression and promote tumour-directed immune responses have been extensively explored in rodent models and in large clinical trials of tumour immunotherapy. This Review describes vaccination approaches investigated for the treatment of glioma. Several strategies have reached phase III clinical trials, including vaccines targeting epidermal growth factor receptor variant III, and the use of either immunogenic peptides or tumour lysates to stimulate autologous dendritic cells. Other approaches in early phases of clinical development employ multipeptide vaccines such as IMA-950, cytomegalovirus-derived peptides, or tumour-derived peptides such as heat shock protein-96 peptide complexes and the Arg132His mutant form of isocitrate dehydrogenase. However, some preclinical trial data suggest that addition of immunomodulatory reagents such as immune checkpoint inhibitors, transforming growth factor-β inhibitors, signal transducer and activator of transcription 3 inhibitors, or modifiers of tryptophan metabolism could augment the therapeutic activity of vaccination and overcome glioma-associated immunosuppression.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

June 2017

Volume

13

Issue

6

Start / End Page

363 / 374

Location

England

Related Subject Headings

  • Vaccination
  • Humans
  • Glioma
  • Cancer Vaccines
  • Brain Neoplasms
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M., & Sampson, J. H. (2017). Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol, 13(6), 363–374. https://doi.org/10.1038/nrneurol.2017.64
Weller, Michael, Patrick Roth, Matthias Preusser, Wolfgang Wick, David A. Reardon, Michael Platten, and John H. Sampson. “Vaccine-based immunotherapeutic approaches to gliomas and beyond.Nat Rev Neurol 13, no. 6 (June 2017): 363–74. https://doi.org/10.1038/nrneurol.2017.64.
Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017 Jun;13(6):363–74.
Weller, Michael, et al. “Vaccine-based immunotherapeutic approaches to gliomas and beyond.Nat Rev Neurol, vol. 13, no. 6, June 2017, pp. 363–74. Pubmed, doi:10.1038/nrneurol.2017.64.
Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017 Jun;13(6):363–374.

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

June 2017

Volume

13

Issue

6

Start / End Page

363 / 374

Location

England

Related Subject Headings

  • Vaccination
  • Humans
  • Glioma
  • Cancer Vaccines
  • Brain Neoplasms
  • Animals